分次立体定向放疗联合化疗对比单纯化疗治疗贝伐珠单抗耐药高级别胶质瘤的随机前瞻性试验
这项单机构随机试验纳入35例贝伐珠单抗治疗后进展的复发性高级别胶质瘤患者,比较分次立体定向放疗(FSRS)联合贝伐珠单抗为基础化疗与单纯贝伐珠单抗为基础化疗。FSRS组2个月局部控制率和无进展生存期均显著优于单纯化疗组,总生存期无显著差异。
要点
- FSRS联合贝伐珠单抗化疗可显著改善贝伐珠单抗耐药复发性高级别胶质瘤的2个月局部控制率。
- FSRS联合治疗组中位无进展生存期显著延长(5.1 vs 1.8个月,P < .001)。
- 总生存期两组无显著差异(7.2 vs 4.8个月,P = .11)。
核心结论
- 对于贝伐珠单抗治疗后进展的复发性高级别胶质瘤患者,FSRS联合贝伐珠单抗为基础化疗可行,且较单纯贝伐珠单抗为基础化疗改善局部控制和无进展生存期。
研究设计与样本
- 单机构随机前瞻性试验,纳入35例经2次既往治疗后进展且正在使用贝伐珠单抗的高级别胶质瘤患者,随机分配至FSRS联合贝伐珠单抗为基础化疗组或贝伐珠单抗为基础化疗组。
- FSRS剂量为大体肿瘤体积32 Gy(8 Gy×4次,2周内),临床靶体积(FLAIR异常区)24 Gy(6 Gy×4次)。
- 主要终点为2个月局部控制率和无进展生存期。
主要发现
- 35例患者中29例为胶质母细胞瘤(WHO IV级),6例为间变性胶质瘤(WHO III级),既往复发中位次数为3次。
- FSRS组中位无进展生存期显著优于单纯化疗组(5.1 vs 1.8个月,P < .001)。
- FSRS组2个月局部控制率显著优于单纯化疗组(82% [14/17] vs 27% [4/15],P = .002)。
- 总中位生存期为6.6个月,FSRS组7.2个月 vs 单纯化疗组4.8个月,差异无统计学意义(P = .11)。
临床怎么用
- 对于贝伐珠单抗耐药的复发性高级别胶质瘤,可考虑在贝伐珠单抗为基础化疗上联合FSRS以改善局部控制和无进展生存。
- 需注意该联合方案未显示总生存获益,应与患者充分沟通预期获益与局限。
局限性
- 单机构随机试验,样本量较小(35例),结果需更大规模多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Outcomes for patients with recurrent high-grade glioma (HGG) progressing on bevacizumab (BEV) are dismal. Fractionated stereotactic radiosurgery (FSRS) has been shown to be feasible and safe when delivered in this setting, but prospective evidence is lacking. This single-institution randomized trial compared FSRS plus BEV-based chemotherapy versus BEV-based chemotherapy alone for BEV-resistant recurrent malignant glioma. MATERIALS AND METHODS: HGG patients on BEV with tumor progression after 2 previous treatments were randomized to 1) FSRS plus BEV-based chemotherapy or 2) BEV-based chemotherapy with irinotecan, etoposide, temozolomide, or carboplatin. FSRS was delivered as 32 Gy (8 Gy × 4 fractions within 2 weeks) to the gross target volume and 24 Gy (6 Gy × 4 fractions) to the clinical target volume (fluid-attenuated inversion recovery abnormality). The primary endpoints were local control (LC) at 2 months and progression-free survival (PFS). RESULTS: Of the 35 patients enrolled, 29 had glioblastoma (WHO IV) and 6 had anaplastic glioma (WHO III). The median number of prior recurrences was 3. Patients treated with FSRS had significantly improved PFS (5.1 vs 1.8 months, P < .001) and improved LC at 2 months (82% [14/17] vs 27% [4/15], P = .002). The overall median survival was 6.6 months (7.2 months with FSRS vs 4.8 months with chemotherapy alone, P = .11). CONCLUSIONS: FSRS combined with BEV-based chemotherapy in recurrent HGG patients progressing on BEV is feasible and improves LC and PFS when compared to treatment with BEV-based chemotherapy alone.
引用
- Bergman D, Modh A, Schultz L, et al. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. J Neurooncol. 2020. PMID: 32444980. doi:10.1007/s11060-020-03526-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。